These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 27760957)
1. [Administration of Immune Checkpoint Inhibitor for Cancer except for Melanoma and Lung Cancer]. Takeda T; Hattori N; Takeda T; Noda T; Takeda H Gan To Kagaku Ryoho; 2016 Oct; 43(10):1271-1273. PubMed ID: 27760957 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
10. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349 [TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. Eigentler TK; Schlaak M; Hassel JC; Loquai C; Stoffels I; Gutzmer R; Pätzold S; Mohr P; Keller U; Starz H; Ulrich J; Tsianakas A; Kähler K; Hauschild A; Janssen E; Schuler-Thurner B; Weide B; Garbe C J Immunother; 2014 Sep; 37(7):374-81. PubMed ID: 25075567 [TBL] [Abstract][Full Text] [Related]
13. Biology and clinical applications of CD40 in cancer treatment. Fonsatti E; Maio M; Altomonte M; Hersey P Semin Oncol; 2010 Oct; 37(5):517-23. PubMed ID: 21074067 [TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy? Renner A; Burotto M; Rojas C J Glob Oncol; 2019 Jul; 5():1-5. PubMed ID: 31348737 [TBL] [Abstract][Full Text] [Related]